315 related articles for article (PubMed ID: 35654659)
1. Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
Grivas P; Kopyltsov E; Su PJ; Parnis FX; Park SH; Yamamoto Y; Fong PC; Tournigand C; Climent Duran MA; Bamias A; Caserta C; Chang J; Cislo P; di Pietro A; Wang J; Powles T
Eur Urol; 2023 Apr; 83(4):320-328. PubMed ID: 35654659
[TBL] [Abstract][Full Text] [Related]
2. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
Lee JL; Desai C; Park SH; Tsuchiya N; Su PJ; Chan TTW; Gurney H; Gao S; Wang J; Sandner R; di Pietro A; Eto M
Urol Oncol; 2023 May; 41(5):256.e17-256.e25. PubMed ID: 37019764
[TBL] [Abstract][Full Text] [Related]
3. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
Grivas P; Park SH; Voog E; Caserta C; Gurney H; Bellmunt J; Kalofonos H; Ullén A; Loriot Y; Sridhar SS; Yamamoto Y; Petrylak DP; Sternberg CN; Gupta S; Huang B; Costa N; Laliberte RJ; di Pietro A; Valderrama BP; Powles T
Eur Urol; 2023 Jul; 84(1):95-108. PubMed ID: 37121850
[TBL] [Abstract][Full Text] [Related]
4. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.
Tomita Y; Yamamoto Y; Tsuchiya N; Kanayama H; Eto M; Miyake H; Powles T; Yoshida M; Koide Y; Umeyama Y; di Pietro A; Uemura H
Int J Clin Oncol; 2022 Feb; 27(2):383-395. PubMed ID: 34973108
[TBL] [Abstract][Full Text] [Related]
5. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
Sridhar SS; Powles T; Climent Durán MÁ; Park SH; Massari F; Thiery-Vuillemin A; Valderrama BP; Ullén A; Tsuchiya N; Aragon-Ching JB; Gupta S; Petrylak DP; Bellmunt J; Wang J; Laliberte RJ; di Pietro A; Costa N; Grivas P; Sternberg CN; Loriot Y
Eur Urol; 2024 Feb; 85(2):154-163. PubMed ID: 37714742
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan.
Su PJ; Xiao Y; Lin AY; Goh C; Wu E; Liu K; Chou P; Kuo K; Palencia R; Chang J; Kearney M; Kapetanakis V; Benedict A
Cancer Rep (Hoboken); 2023 Oct; 6(10):e1887. PubMed ID: 37640556
[TBL] [Abstract][Full Text] [Related]
7. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
Powles T; Park SH; Caserta C; Valderrama BP; Gurney H; Ullén A; Loriot Y; Sridhar SS; Sternberg CN; Bellmunt J; Aragon-Ching JB; Wang J; Huang B; Laliberte RJ; di Pietro A; Grivas P
J Clin Oncol; 2023 Jul; 41(19):3486-3492. PubMed ID: 37071838
[No Abstract] [Full Text] [Related]
8. Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial.
Vignani F; Tambaro R; De Giorgi U; Giannatempo P; Bimbatti D; Carella C; Stellato M; Atzori F; Aieta M; Masini C; Hamzaj A; Ermacora P; Veccia A; Scandurra G; Gamba T; Ignazzi G; Pignata S; Di Napoli M; Lolli C; Procopio G; Pierantoni F; Zonno A; Santini D; Di Maio M;
Eur Urol; 2023 Jan; 83(1):82-89. PubMed ID: 36216658
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States.
Peng Y; She Z; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
Adv Ther; 2021 Dec; 38(12):5710-5720. PubMed ID: 34693504
[TBL] [Abstract][Full Text] [Related]
10. Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.
Powles T; Park SH; Voog E; Caserta C; Valderrama BP; Gurney H; Kalofonos H; Radulovic S; Demey W; Ullén A; Loriot Y; Sridhar SS; Tsuchiya N; Kopyltsov E; Sternberg CN; Bellmunt J; Aragon-Ching JB; Petrylak DP; Laliberte RJ; Huang B; Costa N; Blake-Haskins JA; Grivas P
Future Oncol; 2022 Jun; 18(19):2361-2371. PubMed ID: 35416053
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.
Porte F; Granghaud A; Chang J; Kearney M; Morel A; Plessala I; Cawston H; Roiz J; Xiao Y; Solbes MN; Lambert P; Ravaud A; Loriot Y; Thiery-Vuillemin A; Lévy P
PLoS One; 2024; 19(5):e0302548. PubMed ID: 38728337
[TBL] [Abstract][Full Text] [Related]
12. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
Powles T; Park SH; Voog E; Caserta C; Valderrama BP; Gurney H; Kalofonos H; Radulović S; Demey W; Ullén A; Loriot Y; Sridhar SS; Tsuchiya N; Kopyltsov E; Sternberg CN; Bellmunt J; Aragon-Ching JB; Petrylak DP; Laliberte R; Wang J; Huang B; Davis C; Fowst C; Costa N; Blake-Haskins JA; di Pietro A; Grivas P
N Engl J Med; 2020 Sep; 383(13):1218-1230. PubMed ID: 32945632
[TBL] [Abstract][Full Text] [Related]
13. The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
Hoffman-Censits J; Grivas P; Powles T; Hawley J; Tyroller K; Seeberger S; Guenther S; Jacob N; Mehr KT; Hahn NM
Future Oncol; 2024 Feb; 20(4):179-190. PubMed ID: 37671748
[TBL] [Abstract][Full Text] [Related]
14. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
Grivas P; Agarwal N; Pal S; Kalebasty AR; Sridhar SS; Smith J; Devgan G; Sternberg CN; Bellmunt J
Cancer Treat Rev; 2021 Jun; 97():102187. PubMed ID: 33839438
[TBL] [Abstract][Full Text] [Related]
15. TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
Coquan E; Clarisse B; Lequesne J; Brachet PE; Nevière Z; Meriaux E; Bonnet I; Castera M; Goardon N; Boutrois J; Travers R; Joly F; Grellard JM; Thiery-Vuillemin A
BMC Cancer; 2022 Nov; 22(1):1213. PubMed ID: 36434554
[TBL] [Abstract][Full Text] [Related]
16. Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma-A Cost-Effectiveness Analysis.
Lin D; Luo S; Lin S; Zhong L; Zhou W; Gu D; Huang X; Chen Q; Xu X; Weng X
Clin Genitourin Cancer; 2023 Feb; 21(1):8-15. PubMed ID: 36328903
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma.
Xie Q; Zheng H; Chen Y; Peng X
Front Public Health; 2022; 10():837854. PubMed ID: 35570929
[TBL] [Abstract][Full Text] [Related]
18. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.
Grivas P; Grande E; Davis ID; Moon HH; Grimm MO; Gupta S; Barthélémy P; Thibault C; Guenther S; Hanson S; Sternberg CN
ESMO Open; 2023 Dec; 8(6):102050. PubMed ID: 37976999
[TBL] [Abstract][Full Text] [Related]
19. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland.
Critchlow S; Bullement A; Crabb S; Jones R; Christoforou K; Amin A; Xiao Y; Kapetanakis V; Benedict Á; Chang J; Kearney M; Eccleston A
Future Oncol; 2024 Mar; 20(8):459-470. PubMed ID: 37529943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
